Incidence, risk factors and severity of retinopathy of prematurity in Turkey (TR-ROP study): a prospective, multicentre study in 69 neonatal intensive care units

Ahmet Yagmur Bas,1 Nihal Demirel,1 Esin Koc,2 Dilek Ulubas Isik,3 Ibrahim Murat Hirfanoglu,2 Turan Tunc,4 on behalf of the TR-ROP Study Group

ABSTRACT
Background To evaluate the prevalence, risk factors and treatment of retinopathy of prematurity (ROP) in Turkey and to establish screening criteria for this condition.

Methods A prospective cohort study (TR-ROP) was performed between 1 April 2016 and 30 April 2017 in 69 neonatal intensive care units (NICUs). Infants with a birth weight (BW)≤1500 g or gestational age (GA)≤32 weeks and those with a BW>1500 g or GA>32 weeks with an unstable clinical course were included in the study. Predictors for the development of ROP were determined by logistic regression analyses.

Results The TR-ROP study included 6115 infants: 4964 (81%) with a GA≤32 weeks and 1151 (19%) with a GA>32 weeks. Overall, 27% had any stage of ROP and 6.7% had severe ROP. A lower BW, smaller GA, total days on oxygen, late-onset sepsis, frequency of red blood cell transfusions and relative weight gain were identified as independent risk factors for severe ROP in infants with a BW≤1500 g. Of all infants, 414 needed treatment and 395 (95.4%) of the treated infants had a BW≤1500 g. The early treatment for Retinopathy of Prematurity requirements were followed. Screening of infants with a GA≤34 weeks or a BW<1700 g appears to be appropriate in Turkey. Monitoring standards of neonatal care and conducting quality improvement projects across the country are recommended to improve neonatal outcomes in Turkish NICUs.

Trial registration number NCT02814929, Results.

INTRODUCTION
Retinopathy of prematurity (ROP), a vasoproliferative disorder of the immature retina in premature infants, is a significant cause of blindness in many middle-income countries. The prevalence of ROP is lower in high-income countries, where risk factors such as oxygen administration and blood oxygen saturation are strictly monitored.1 Severe ROP is typically found in infants with a very low gestational age (GA) at birth in developed countries.1,2 Heavier and more mature babies can also develop ROP in developing countries, because there is insufficient awareness of the risk factors of the disease process, a shortage of skilled professionals and/or a shortage of essential equipment to care for infants.2

In recent years, Turkey has been developing programmes to improve neonatal health. This study (TR-ROP) determined the prevalence and treatment modalities of infants with ROP in Turkey and was the first multicentre study to analyse risk factors for ROP development in the country. Based on data obtained from infants, criteria for ROP screening in Turkey were evaluated. Because Turkey has received many refugees in recent years, this study also evaluated the prevalence of ROP in preterm infants born to refugees.

METHODS
The TR-ROP study was promoted by the Turkish Neonatology Society and included preterm infants screened for ROP between 1 April 2016 and 30 April 2017. In Turkey, the total number of neonatal intensive care units (NICUs) including neonatologists on the medical staff is 134 (22 private, 40 university and 72 state hospitals). In total, 69 NICUs (8 private, 39 university and 22 state hospitals) agreed to take part in the study (51% of all). Heads of the NICUs and directors of hospitals gave written consent to participate in the research. It was approved by the ethics committee and informed consent was obtained from the parents before the initial screening.

Study population
This prospective cohort study evaluated the incidence and severity of ROP in relation to GA, birth weight (BW) and treatment modalities. The independent risk factors for the development of severe ROP in infants with a BW≤1500 g and for any ROP in infants with a BW>1500 g were assessed.

Infants with a BW≤1500 g or GA≤32 weeks and those with a BW>1500 g or GA>32 weeks, who were determined by the attending clinician to be at risk for ROP development, were screened. Then the medical records of retinal examinations of preterm infants who met the screening criteria were evaluated. The data on refugee infants were also recorded. Examinations took place in the NICU or outpatient facility (for discharged infants). Eligible infants who were discharged before the first screening and missed or did not complete all screening sessions were excluded from the study. The data are restricted to all babies who underwent all the screening sessions. Infants with congenital anomalies, chromosomal abnormalities and
those who died before the first ophthalmic examination were excluded from the study.

Dataset
Neonatologists who agreed to participate in this study provided data regarding ROP in their NICUs. A case report form (CRF) for each enrolled patient was completed by the participating neonatologist. Data were collected through an online data entry system via a special network named the ‘Trials-Network’. All the questions in the CRF were required to be answered. The data entry system did not allow the collaborator to proceed and submit the data if no response was received for any question in the CRF. Anonymous data were entered into password protected database to maintain confidentiality. The records from 69 NICUs were pooled together and analysed at the end of the study.

Clinical characteristics
Antenatal, natal and postnatal risk factors for the development of ROP including maternal age, use of antenatal corticosteroids, preeclampsia/eclampsia, infants of diabetic mothers, chorioamnionitis (clinical or histopathological), in vitro fertilisation, multiple births, mode of delivery, sex, GA, BW, small for gestational age (SGA; 10th percentile), resuscitation in the delivery room, respiratory distress syndrome (RDS), surfactant treatment, duration of invasive/noninvasive mechanical ventilation and oxygen therapy, intracranial haemorrhage >Grade II according to Papile staging, haemodynamically significant patent ductus arteriosus (PDA), early/late neonatal sepsis (clinically proven or culture positive), necrotising enterocolitis (NEC) ≥Stage II in accordance with the modified Bell criteria, the number of red blood cell (RBC) transfusions (15 mL/kg for each transfusion), bronchopulmonary dysplasia (BPD), oxygen requirement at 36 weeks postmenstrual age, relative weight gain and breastfeeding were recorded on the CRF for each patient.

Ophthalmic examinations
The International Classification of ROP guidelines were used to record the stage of the disorder, location by zone and signs of plus disease. All infants meeting the screening criteria were scheduled to have their first examination at between 4 and 6 weeks of life. Ophthalmic examinations were continued until full retinal vascularisation and the maximum stage of ROP for each infant was reported. The data were analysed for the most advanced stage of ROP in the eye with the most severe disease. Severe ROP was defined as ROP needing treatment. Criteria for treatment of ROP were based on the Early Treatment for Retinopathy of Prematurity (ETROP); however, not all treated patients met this criteria and were defined as the ‘unclassified’ group. The study also investigated the need for laser photocoagulation, intravitreal bevacizumab (IVB) and vitreorectal surgery for ROP.

The NICUs having no treatment options transferred the infants to other facilities where ROP treatment is available. The referring neonatologists completed the CRF forms for these patients after being in contact with the receiving facilities.

Statistical analyses
Statistical analyses were conducted using SPSS statistical software for Windows, V.21.0 (SPSS, Chicago, Illinois, USA). The results are presented as numbers (n), frequencies (%), means with the respective SDs and medians with their IQRs. Parametric tests were used to analyse variables. The \( \chi^2 \) test was used to compare categorical variables. A two-tailed value of \( p\leq 0.05 \) was considered statistically significant. Multiple logistic regression analyses were used to evaluate risk factors for any degree of ROP (BW > 1500 g) and severe ROP in infants (BW ≤ 1500 g), using the selection of factors associated (\( p\leq 0.05 \)) with ROP determined by univariate analyses. In the model, no ROP versus severe ROP (BW ≤ 1500 g) and no ROP versus any degree of ROP (BW > 1500 g) were compared. Variables with a \( p\leq 0.05 \) using logistic regression analyses were accepted as independent risk factors. The OR and 95% CI for each risk factor were determined. The one-way analysis of variance was performed to determine the statistical significance for GA and BW among NICUs in university, state and private hospitals.

RESULTS
During the study period, data from 69 centres including NICUs of 39 university hospitals (2823 infants), 22 state hospitals (2605 infants) and 8 private hospitals (687 infants) were obtained. All of the participating centres had ophthalmology units for ROP screening, but only 41/69 performed laser photocoagulation and/or antivascular endothelial growth factor (anti-VEGF) treatments and 5/69 centres performed vitreoretinal surgery.

The TR-ROP study included 6115 preterm infants: 4964 (81%) with a GA ≤ 32 weeks and 1151 (19%) with a GA > 32 weeks. The mean BW and GA for the total cohort were 1,457 ± 479 g and 28.9 ± 6.3 weeks, respectively. There were 3163 (51.7%) females and 2952 (48.3%) males in the study group. The mean postnatal day and postmenstrual age at the initial diagnosis of ROP were 49.2 ± 16 days and 33.8 ± 2.9 weeks, respectively. Overall, 27% of the patients were found to have any stage of ROP and 6.7% had severe ROP. The incidences of ROP and severe ROP in relation to GA and BW are shown in table 1. The majority (96%) of infants with any stage of ROP had a GA ≤ 32 weeks and 80% of the infants with severe ROP had a GA ≤ 28 weeks.

Of the total study cohort, a total of 551 infants (9%) were born to refugees. There were no statistically significant differences in any degree of ROP and severe ROP between very low birth weight (VLBW) infants of citizens (n=3193) and refugees (n=297).

Univariate analyses identified several risk factors as potential markers. Table 2 shows the relationships between severe ROP and risk factors in infants with a BW ≤ 1500 g.

---

Table 1 ROP in relation to gestational age and birth weight

| Gestational age (weeks) | Screened infants (n) | Any ROP (n, %) | Severe ROP (n, %) |
|------------------------|----------------------|----------------|------------------|
| ≤28                    | 1539                 | 968 (62.9)     | 332 (21.6)       |
| 29–32                  | 3425                 | 666 (19.4)     | 76 (2.2)         |
| Subtotal (≤32)         | 4964                 | 1634 (32.9)    | 409 (8.2)        |
| 33–35                  | 1030                 | 56 (5.4)       | 6 (0.6)          |
| Subtotal (>35)         | 121                  | 5 (4.1)        | –                |
| Total                  | 6115                 | 1695 (27)      | 414 (6.7)        |

ROP, retinopathy of prematurity.
All risk factors found to be significant were analysed using a multivariate logistic regression model. Table 3 shows the independent risk factors for severe ROP in VLBW infants.

Using multivariate logistic regression analyses, the following were independent risk factors for any ROP in infants with BW >1500 g: GA (for every 100 g) (OR, 0.863; 95% CI 0.775 to 0.960; p=0.007), BW (for every week) (OR, 0.997; 95% CI 0.996 to 0.998; p<0.001), RBC transfusion (>once) (OR, 1.545; CI 1.067 to 2.237; p=0.021) and total days on oxygen (for each day on oxygen) (OR, 1.023; CI 1.014 to 1.032; p<0.001).

Of all of the infants screened for ROP, 414 (6.7%) needed treatment. A total of 395 (95.4%) of the treated infants had a BW ≤1500 g and treatment was performed in 19 infants with a BW of 1501–2000 g. Severe ROP was diagnosed in five babies with BW >1500 g and GA >32 weeks who required treatment. Treatment was applied bilaterally in 385 patients and was performed in one eye in 29 cases. Five infants with a GA ≤32 weeks underwent vitreoretinal surgery. Table 4 lists the severities and treatment modalities of ROP in the treated patients.

The incidence of severe ROP in university hospitals, in state hospitals and in private hospitals was 6.2%, 6.8% and 8.4% respectively. Mean GA and mean BW of infants with severe ROP versus those with no ROP, defined as p<0.05; PDA, patent ductus arteriosus; PN, postnatal; RBC, red blood cell; RDS, respiratory distress syndrome; ROP, retinopathy of prematurity; SGA, small for gestational age.

**Table 2** Univariate analyses of covariates for severe ROP development in infants with a BW ≤1500 g

| Covariates                        | Infants BW ≤1500 g | Univariate analysis (Severe ROP vs No ROP) |
|-----------------------------------|--------------------|---------------------------------------------|
|                                   | No ROP (n=2022)    | Severe ROP (n=395)                          | P value | 95% CI | OR    |
| Maternal age (years)*             | 28.9±6.4           | 28.7±6.2                                    | 0.565   | 0.979  | 1.012 | 0.995 |
| Antenatal steroid, two doses      | 870 (43%)          | 145 (36.7 %)                                | 0.02†   | 0.614  | 0.995 | 0.767 |
| Preeclampsia                      | 544 (26 %)         | 83 (21 %)                                   | 0.015†  | 0.556  | 0.938 | 0.722 |
| Gestational diabetes              | 106 (5 %)          | 23 (5.8 %)                                  | 0.640   | 0.702  | 1.177 | 1.117 |
| Chorioamnionitis                  | 165 (8 %)          | 56 (14 %)                                   | <0.001† | 1.343  | 2.570 | 1.858 |
| IVF pregnancy                     | 247 (12%)          | 41 (10 %)                                   | 0.832   | 0.586  | 1.180 | 0.832 |
| Multiple births                   |                    |                                             |         |        |       |       |
| Twins                             | 424 (21%)          | 80 (20.3 %)                                 | 0.728   | 0.729  | 1.248 | 0.953 |
| Triplets                          | 76 (3.8 %)         | 14 (3.5 %)                                  | 0.810   | 0.519  | 1.068 | 0.931 |
| Vaginal delivery                  | 236 (12 %)         | 83 (21 %)                                   | <0.001† | 1.524  | 2.656 | 2.012 |
| Gestational age (weeks)*          | 29.8±2.2           | 26.5±1.9                                    | <0.001† | 0.441  | 0.511 | 0.475 |
| BW (g)*                           | 1215±215           | 888±218                                     | <0.001† | 0.994  | 0.992 | 0.994 |
| Male gender                       | 934 (46 %)         | 207 (52 %)                                  | 0.028†  | 1.035  | 1.593 | 1.284 |
| SGA                               | 520 (25.7 %)       | 50 (12.7 %)                                 | <0.001† | 0.306  | 0.572 | 0.418 |
| Resuscitation at birth            | 853 (42 %)         | 306 (77 %)                                  | <0.001† | 3.667  | 6.070 | 4.717 |
| RDS                               | 1228 (63 %)        | 361 (91 %)                                  | <0.001† | 4.820  | 9.957 | 6.928 |
| Surfactant treatment              | 959 (47 %)         | 340 (86 %)                                  | <0.001† | 5.092  | 9.240 | 6.859 |
| Duration of invasive mechanical ventilation (days)* | 0±2 (0–148) | 17±40 (0–308) | <0.001† | 1.063  | 1.080 | 1.071 |
| Duration of noninvasive ventilation (days)* | 3±7 (0–87) | 18±22 (0–120) | <0.001† | 1.079  | 1.100 | 1.090 |
| Total days on oxygen*             | 10±23 (0–171)      | 65±35 (0–308)                               | <0.001† | 1.047  | 1.057 | 1.052 |
| PDA requiring treatment           | 349 (36 %)         | 210 (52 %)                                  | <0.001† | 4.326  | 6.837 | 5.438 |
| Intracranial haemorrhage (>Grade II) | 73 (3.6 %) | 70 (17.7 %)                                 | <0.001† | 4.075  | 8.142 | 5.748 |
| Early-onset neonatal sepsis       | 433 (21 %)         | 167 (42 %)                                  | <0.001† | 2.149  | 3.378 | 2.694 |
| Late-onset neonatal sepsis        | 677 (33 %)         | 294 (74 %)                                  | <0.001† | 4.537  | 7.394 | 5.792 |
| NEC (≥Stage II)                   | 142 (7 %)          | 84 (21 %)                                   | <0.001† | 2.680  | 4.840 | 3.601 |
| BPD                               | 273 (13 %)         | 266 (67 %)                                  | <0.001† | 10.324 | 16.884 | 13.203 |
| Frequency of RBC transfusions     |                    |                                             |         |        |       |       |
| Once                              | 426 (21 %)         | 41 (10 %)                                   | <0.001† | 2.637  | 7.503 | 4.448 |
| Twice and more                    | 532 (26 %)         | 331 (83 %)                                  | <0.001† | 18.607 | 44.438 | 28.756 |
| Breastfeeding more than 80% of feeding at PN 28 days, (n, %) | 1347 (66 %) | 9 (17.7 %) | 0.018 | 1.023 | 1.032 | 0.996 |
| Age of regain BW (days)*          | 11.3±5.1           | 14.5±6                                      | <0.001† | 1.080  | 1.121 | 1.100 |
| Relative weight gain at 28 days (g)* | 382±180           | 229±135                                     | <0.001† | 0.993  | 0.995 | 0.994 |

*The values are presented as means±SD.
†The values are presented as median±IQR, min-max values are given in parentheses.
‡The variables that were put in the logistic regression model.

DISCUSSION

ROP is a serious morbidity of prematurity, whose incidence and severity increase with decreasing GA and BW. Studies conducted in high-income countries have shown that infants born at ≥32
weeks are not at risk for developing ROP and most infants born at >28 weeks who develop ROP have a mild disease that spontaneously regressed without treatment. The findings of the TR-ROP study were comparable to those from other developing countries and showed that more mature and heavier babies were at risk for severe ROP.

There were no differences in any ROP and severe ROP development between VLBW infants of refugees and citizens in our study. The Ministry of Health of Turkey has been involved in direct healthcare services in the refugee camps and through the referral of refugees to Turkish hospitals. The 2015 report of the Turkish Neonatology Society reported a mortality rate of 26% for babies with a BW<1500 g, according to data obtained from 59 NICUs. However, there were insufficient data on the neonatal mortality of refugees in this report.

GA, BW and oxygen therapy are well-known major risk factors in the development of ROP. In this study, a lower BW, shorter GA and total days on oxygen were found as independent risk factors for severe ROP in infants with a BW≤1500 g and for any ROP in infants with a BW>1500 g.

Some previous studies have reported that the prevalence of ROP was higher in SGA infants compared with appropriate for GA preterms, while SGA was not found to be a risk factor for ROP in other reports. Factors that are considered an increased risk for severe ROP in SGA babies include chronic uterine hypoxia, abnormal growth factor levels, nutrient restriction and antioxidative deficiency. However, in our study, SGA was surprisingly associated with a decreased incidence of severe ROP in VLBW infants when using a multivariate logistic regression model.

There was a relationship between poor postnatal weight gain and an increased risk for ROP. Poor postnatal weight gain was also found as an independent risk factor for severe ROP in infants with a BW≤1500 g in our study. Using univariate analyses, several risk factors including RDS, respiratory support, sepsis, NEC, PDA, intracranial haemorrhage and BPD were significantly associated with severe ROP in VLBW infants in our cohort. These perinatal morbidities may have decreased postnatal weight gains.

This study showed that RBC transfusions had strong effects on the development of ROP. Transfusions may increase oxygen delivery to the retina because of the lower oxygen affinity of adult haemoglobin in packed red cells. Repeated transfusions may also cause free iron accumulation, which may result in increased production of free hydroxyl radicals as assessed by the Fenton reaction, resulting in damage to the retina. Although the role of blood transfusions as a risk factor for ROP was suggested by numerous reports, several studies have reported that a transfusion limitation policy did not reduce the prevalence of ROP. Our data suggested that limiting blood transfusion in regards to threshold haemoglobin values in guidelines could contribute to reducing the prevalence of ROP.

Multiple studies have reported the role of neonatal sepsis in the development of ROP. In this study, late onset sepsis was an independent risk factor for severe ROP in VLBW infants. Sepsis may act through cytokines and endotoxins, which directly affect retinal angiogenesis. This process is frequently accompanied by hypotension, which can cause tissue perfusion impairment and retnal ischaemia.

Treatment was performed in 6.7% of the infants screened for ROP in the current study. In nearly half of the infants with severe ROP, the treatment modality involved laser photocoagulation and IVB was performed in the other half as the first choice.

Clinical science

### Table 3: Independent risk factors for severe retinopathy of prematurity in infants with a birth weight<1500 g

| Risk Factor                      | OR     | 95% CI          | P value |
|----------------------------------|--------|-----------------|---------|
| Gestational age (weeks)*         | 0.812  | 0.726 to 0.910  | <0.001  |
| Birth weight (g)†                 | 0.998  | 0.997 to 0.999  | <0.001  |
| Small for gestational age         | 0.471  | 0.277 to 0.799  | 0.005   |
| Total days on oxygen‡             | 1.025  | 1.019 to 1.031  | <0.001  |
| Late-onset sepsis                 | 1.423  | 1.016 to 1.994  | 0.04    |
| Frequency of red blood cell       | 2.384  | 1.389 to 4.092  | 0.002   |
| transusions≥twice                 |        |                 |         |
| Relative weight gain at 28 days   | 0.998  | 0.997 to 0.999  | <0.001  |

P<0.05 represents statistical significance.
* OR for every week.
† OR for every 1 g.
‡ OR for each day on oxygen.

### Table 5: Mean BWs and GAs of infants with severe ROP according to types of units

| Type of Unit                      | University hospitals (n=192) | State hospitals (n=164) | Private hospitals (n=58) | P value* |
|-----------------------------------|------------------------------|-------------------------|--------------------------|---------|
| Mean GA (weeks)                   | 26.3±2                       | 26.7±2.2                | 27.9±2.1                 | <0.05   |
| Mean BW (g)                       | 878±250                      | 905±273                 | 1128±299                 | <0.05   |

*The values are significantly higher in private hospitals than in university and state hospitals.

BW, birth weight; GA, gestational age; n, number of patients; ROP, retinopathy of prematurity.
A nationwide population-based study from the UK reported that diode laser photoagulation was performed in 90.5% of infants requiring treatment. The higher usage of IVB in our study may be due to ease of administration (typically at the bedside). In addition, paediatric anaesthesia for performing laser photoagulation was not available in some NICUs in our study.

Notably, 66 (16%) of 414 infants were treated earlier than type 1 ROP and did not fulfil the ETROP requirements for treatment in our study. Twenty-six of these 66 infants were treated with IVB. The popularity of anti-VEGF agents is increasing in Turkey; however, the long-term safety and efficacy of these agents are still not definitively known. The risk of progression to retinal detachment in type 1 ROP is around 15%, but is much lower with less severe disease. Evidence-based data are not available to confirm a favourable risk–benefit ratio of IVB usage in cases earlier than type 1 ROP.

In our study, the incidence of severe ROP varied between the three types of NICU which reflects the differences in neonatal care. The rates of severe ROP were lower in university hospital NICUs, where practices for newborn care are likely to be better than non-university NICUs. Based on the results of present study, the screening criteria for ROP need to be wider in state and private hospitals than applied in the university hospitals. ROP programmes in Turkey should adopt the criteria of <1700 g or ≤34 weeks to capture all babies requiring treatment.

The strength of the TR-ROP study was that it was a large multicentre cohort study that allowed us to prospectively obtain data via a special network. However, the neonatologists did not go through any training in order to standardise definitions of potential risk factors before the study started. Similarly, the participating ophthalmologists also did not undergo any processes to standardise how they graded ROP. These situations are the limitations of the study.

In conclusion, screening criteria for ROP in Turkey needs to be wider than developed countries. The high incidence of infants with ROP in our study emphasised the need for aggressive measures for prevention and control of the disease. The safe implementation of oxygen therapy with appropriate monitoring, better antenatal and neonatal care, meticulous attention to hygienic procedures and control of sepsis may reduce the prevalence of ROP. Therefore, monitoring standards of neonatal care and conducting quality improvement projects across the country are essential for improving neonatal outcomes in Turkish NICUs.

Correction notice This article has been corrected since it published Online First. Typos in several of the Collaborator names have been corrected.

Acknowledgements We thank Bulent Celik from the Department of Statistics, Gazi University, Ankara, for statistical analysis.
Competing interests None declared.

Patient consent Guardian consent obtained.

Ethics approval The study was approved by the ethical review committee of Gulhane Faculty of Medicine.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ © Article author(s) (or their employer(s)) unless otherwise stated in the text of the article 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1 Adams GGW, Bunce C, Xing W, et al. Treatment trends for retinopathy of prematurity in the UK. BMJ Open 2017;7:21.

2 Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 2008;84(7–8).

3 Chaudhry TA, Hashmi FK, Salat MS, et al. Retinopathy of prematurity: an evaluation of existing screening criteria in Pakistan. Br J Ophthalmol 2014;98:298–301.

4 Mikolajczyk RT, Zhang J, Bettan AP, et al. A global reference for fetal-weight and birthweight percentiles. Lancet 2011;377:1855–61.

5 Papile LA, Burstein J, Burstein R, et al. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. Pediatr 1978;92:529–34.

6 Bell MJ, Temberg JD, Feigin RD, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg 1978;187:1–7.

7 International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005;123:991–9.

8 Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684–9.

9 Holmström G, Hellström A, Jakobsson P, et al. Evaluation of new guidelines forROP screening in Sweden using SWEDROP – a national quality register. Acta Ophthalmol 2015;93:265–8.

10 Tabarez-Carvajal AC, Montes-Cantillo M, Unkrich KH, et al. Retinopathy of prematurity: screening and treatment in Costa Rica. Br J Ophthalmol 2017;101:7109–13.

11 Society TN. Mortality rates in Turkish NICUs in 2016. Turk Neonatal Soc Bull 2017;29:32–4. Article in Turkish.

12 Phelps DL. Retinopathy of prematurity. In: Martin RJ, Fanaroff AA, Walsh MC, eds. Fanaroff and Martin’s neonatal perinatal medicine: diseases of the fetus and infant. Philadelphia: Elsevier Saunders; 2015:1767–74.

13 Bernstein IM, Horbar JD, Badger GJ, et al. Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction. The Vermont Oxford Network. Am J Obstet Gynecol 2000;182:198–206.

14 Filibo JBF, Vallatii FB, Eckert GJ, et al. Is being small for gestational age a risk factor for retinopathy of prematurity? A study with 345 very low birth weight preterm infants. J Pediatr 2009;85:94–58.

15 Kavurt S, Özcan B, Aydemir O, et al. Risk of retinopathy of prematurity in small for gestational age premature infants. Indian Pediatr 2014;51:804–6.

16 Hellström A, Härd AL, Engström E, et al. Early weight gain predicts retinopathy in preterm infants: new, simple, efficient approach to screening. Pediatrics 2009;123:e638–e645.

17 Wardle SP, et al. Effect of blood transfusion on lipid peroxidation in preterm infants. Arch Dis Child Fetal Neonatal Ed 2002;86:467–8.

18 Heise L, Ebert W, Schlaud M, et al. Blood transfusion. Iron load and retinopathy of prematurity. Eur J Pediatr 1997;156:465–70.

19 Dani C, Reali MF, Bertini G, et al. The role of blood transfusions and iron intake on retinopathy of prematurity. Early Hum Dev 2001;62:57–63.

20 Kipraliani H, Whyke RK, Andersen C, et al. The Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants. J Pediatr 2006;149:301–7.

21 Tolosa KX, Alired EN, Chen MI, et al. Neonatal bacteriaemia and retinopathy of prematurity: the ELGAN study. Arch Ophthalmol 2011;129:155–63.

22虱江, B, 汉森 NI, Adams-Chapman J, et al. Neuromotor development and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA 2004;292:2357–60.

23 Lee J, Dammann O. Perinatal infection, inflammation, and retinopathy of prematurity. Semin Fetal Neonatal Med 2012;17:26–9.